Morepen Laboratories Limited
MOREPENLAB.NS
National Stock Exchange of India60.78
INR
+1.71
- -
Morepen Laboratories Limited
MOREPENLAB.NS
(National Stock Exchange of India)
Recent
price
60.78
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Morepen Laboratories Limited is an Indian pharmaceutical company engaged in the development, manufacturing, marketing, and sale of a broad range of active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products. The company's core products include APIs across therapeutic categories such as anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; branded formulations in cardiology, diabetology, gastroenterology, antibiotics, gynecology, central nervous system, and nutraceuticals; and home diagnostic products including glucometers, blood glucose test strips, blood pressure monitors, nebulizers, digital thermometers, pulse oximeters, and air purifiers. The company also markets over-the-counter products under the Dr. Morepen brand such as Fever X, Pain X, Fiber-X, and Burnol. Morepen holds market leadership in India with significant shares in APIs for drugs like Montelukast, Loratadine, Desloratadine, and Fexofenadine. It operates in India, the United States, and international markets from its headquarters in Gurugram, India, with manufacturing facilities including USFDA-approved plants. Recent significant developments include the launch of four new products in April 2025—Ticapen, UdoFix, LycoMore, and Acifix—targeting critical therapeutic areas including cardiology, hepatology, nutrition, and diabetology, supported by APIs manufactured in-house to ensure quality and supply reliability. The company expanded its medical devices portfolio through the incorporation of a new step-down subsidiary, Sigmacheck Health Private Limited, in August 2025, aiming to diversify and capitalize on the growing healthcare equipment sector. Additionally, the company renamed its subsidiary Morepen Medtech Limited to Morepen Medipath Limited in April 2025, reflecting a strategic repositioning within its medical technology business. Morepen continues to emphasize research and development innovation, demonstrated by its expanded product pipeline and strategic market expansion into tier-2 and tier-3 cities in India, especially in point-of-care diagnostics and home health devices. The company maintains a debt-free status and robust financial health, underscoring operational stability and growth orientation since its founding in 1984. Morepen Laboratories Limited serves both domestic and international pharmaceutical and healthcare markets, catering to hospitals, clinics, retail pharmacies, and direct consumers through its diagnostic and OTC product lines, reinforcing its position as a comprehensive healthcare solutions provider in APIs, formulations, and medical devices. The company is led by Chairman and Managing Director Sushil Suri and continues to invest in expanding its sales force with plans to add medical representatives while strengthening its R&D infrastructure to sustain long-term growth and innovation.